NCT07175441RecruitingPhase 2
Evaluation of RBS2418 in Combination With Tremelimumab Plus Durvalumab in Participants With Advanced Unresectable Hepatocellular Carcinoma
A Phase 2a, Multicenter, Randomized, Open-Label Study to Assess the Efficacy, Safety, and Tolerability of RBS2418 in Combination With Tremelimumab Plus Durvalumab for Participants With Advanced Unresectable Hepatocellular Carcinoma
Source: ClinicalTrials.gov · Last updated 24 Apr 2026
Brief summary (registry, in English)
RBS2418 is a targeted immune modulator that inhibits ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1). It is designed to promote anti-tumor immunity by preserving endogenous 2'-3' cyclic guanosine monophosphate-adenosine monophosphate (cGAMP) from hydrolysis, thereby activating antigen-presenting cells and promoting robust T cell activation. Ideally, RBS2418 acts synergistically with CTLA-4 inhibitors, such as those in the STRIDE regimen (Tremelimumab plus Durvalumab). The hypothesis is that RBS2418 combined with STRIDE will be safe, well-tolerated, highly immunogenic, and enhance anti-tumor responses in adult participants with advanced, unresectable hepatocellular carcinoma (HCC) compared to STRIDE alone.
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 220 (estimated)
- First submitted
- 9 Sept 2025
- Start date
- 10 Apr 2026
- Primary completion date
- 30 Apr 2027
- Lead sponsor
- Riboscience, LLC.
- Diseases
- Liver and biliary tract cancer
- NCT number
- NCT07175441
What you commit to
- Study type: Interventional · Phase 2
- Planned participants: 220
- From 10 Apr 2026 to the primary completion date, 30 Apr 2027
- 4 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- BCLC stage D disease at the time of screening or prior to first dose of RBS2418.
- Child-Pugh class equal or higher than B8 at the time of screening or within 7 days prior to the first dose of study treatment.
- Eligible for curative treatments (e.g., surgical resection, liver transplantation, or local ablation).
- Evidence of rapid progression on prior therapy resulting in rapid clinical deterioration.
Who the study is looking for
- At least 18 years of age on the day of signing informed consent.
- Male and female participants with advanced, unresectable HCC who are eligible to receive STRIDE regimen as first line therapy.
- Willing to submit a pre-treatment tissue sample (archival or fresh tissue if archival is not available).
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (4)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Johns Hopkins Coordinator of this site? Confirm its status | Baltimore | United States | Recruiting |
| University of Texas, Southwestern Coordinator of this site? Confirm its status | Dallas | United States | Recruiting |
| START Dallas Fort Worth Coordinator of this site? Confirm its status | Fort Worth | United States | Recruiting |
| Vanderbilt-Ingram Cancer Center Coordinator of this site? Confirm its status | Nashville | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.